SOURCE: IO News Wire

IO News Wire

September 28, 2010 07:30 ET

(AMEX: CRMD) Given BUY Rating and a 12 Month Price Target of $6.00 by Griffin Securities

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO NewsWire

NEW YORK, NY--(Marketwire - September 28, 2010) -  CorMedix Inc. (NYSE Amex: CRMD) is a specialty pharmaceutical company engaged in the development of therapeutics, devices, and diagnostics for the prevention, treatment and detection of cardio-renal disease.

Griffin Securities' August 2010 Research Report has identified Neutrolin, a CorMedix breakthrough catheter related infection control product, as having the potential for $675 million in sales as their pivotal registration trial begins as early as the first half of 2011.

CorMedix is also developing CRMD001 which is an innovative deferiprone formulation aimed at the removal of excess iron in the body, which is commonly associated with x-ray dyes and imaging procedures. Griffins Research Report estimates this market opportunity at nearly $365 million.

To view the Griffin Securities Report on CorMedix, please visit www.proactivenewsroom.com/cormedix.

Other active stocks are Abbott Laboratories (NYSE: ABT) Keryx Biopharmaceuticals (NASDAQ: KERX) and Healthmed Services (PINKSHEETS: HEME).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information